<DOC>
	<DOCNO>NCT01026493</DOCNO>
	<brief_summary>RATIONALE : Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide . work different way stop growth tumor cell , either kill cell stop divide . Giving veliparib together temozolomide may kill tumor cell . PURPOSE : This randomized phase I/II trial study side effect best dose give veliparib together temozolomide see well work treat patient recurrent glioblastoma .</brief_summary>
	<brief_title>Veliparib Temozolomide Treating Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To define maximum-tolerated dose combination temozolomide veliparib patient recurrent glioblastoma previously treat temozolomide . ( Phase I* ) - To determine efficacy combination temozolomide veliparib ( use 5-day vs 21-day schedule ) measure 6-month progression-free survival rate patient recurrent glioblastoma previously treat temozolomide . ( Phase II* ) Secondary - To characterize safety profile combination temozolomide veliparib . ( Phase I* ) - To determine adverse event profile tolerability combination temozolomide veliparib ( use 5-day vs 21-day schedule ) patient recurrent glioblastoma . ( Phase II* ) - To determine efficacy combination temozolomide veliparib ( use 5-day vs 21-day schedule ) measure objective response patient measurable disease . ( Phase II* ) - To determine overall survival patient measurable disease treat combination temozolomide veliparib ( use 5-day vs 21-day schedule ) . ( Phase II* ) NOTE : *Phase I close phase II open 3/6/12 . OUTLINE : This multicenter , phase I* dose-escalation study follow phase II* randomize study . Patients enrol phase II portion stratify accord bevacizumab status ( bevacizumab-naive v bevacizumab-failure ) , age ( &lt; 50 year vs ≥ 50 year ) , Karnofsky performance status ( 70-80 % vs 90-100 % ) , recent resection ( yes v no/biopsy ) . - Phase I : * Patients receive oral temozolomide daily oral veliparib twice daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Phase II : * Patients randomize 1 2 treatment arm . - Arm I : Patients receive temozolomide veliparib phase I . - Arm II : Patients receive oral temozolomide daily oral veliparib twice daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 12 week 1 year , every 26 week 2 year , annually thereafter . NOTE : *Phase I close phase II open 3/6/12 . PROJECTED ACCRUAL : A total 240 patient ( 28 phase I* 212 phase II* ) accrue study . NOTE : *Phase I close phase II open 3/6/12 .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Any intracranial highgrade glioma ( phase I* ) Glioblastoma gliosarcoma ( phase II* ) Patients whose original histology lowgrade glioma eligible provide subsequently diagnose glioblastoma gliosarcoma Unequivocal radiographic evidence tumor progression MRI within 14 day prior registration stable decrease dose steroid least 5 day prior scan OR recent resection ( registration within 30 day resection ) long follow condition meet : Patients must recover effect surgery Residual disease follow resection recurrent glioblastoma mandate eligibility study ; best ass extent residual disease postoperatively , postoperative MRI scan perform within 28 day prior registration within 96 hour post surgery ( although 24 hour would optimum ) Prior radiation require phase I* arm Patients must complete course radiation therapy least 2 consecutive adjuvant cycle temozolomide ( phase II* ) A stable decrease dose steroid least 5 day prior scan mandate patient recent resection No evidence acute ( i.e. , new active ) intratumoral hemorrhage MRI Patients MRI demonstrate old hemorrhage subacute blood neurosurgical procedure ( biopsy resection ) eligible NOTE : *Phase I close phase II open 3/6/12 . PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL ( transfusion intervention allow ) SGOT ≤ 3.0 time upper limit normal ( ULN ) SGPT ≤ 3.0 time ULN Bilirubin ≤ 1.25 time ULN Creatinine &lt; 1.7 mg/dL OR estimate GFR ≥ 30 mL/min Urine protein : creatinine ratio ≤ 0.5 OR urine protein &lt; 1,000 mg 24hour urine collection** Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy Able undergo brain MRI scan IV gadolinium Able swallow oral medication Patients history seizure , new onset seizure , clinically control seizure least 14 day prior registration No prior invasive malignancy ( except nonmelanomatous skin cancer carcinoma situ cervix ) unless patient diseasefree therapy disease ≥ 3 year No severe , active comorbidity , include follow : Transmural myocardial infarction unstable angina within past 6 month Evidence recent myocardial infarction ischemia indicate ST elevation ≥ 2 mm EKG perform within past 14 day NYHA class IIIV congestive heart failure require hospitalization within past 12 month Stroke transient ischemic attack within past 6 month Cerebral vascular accident within past 6 month Serious inadequately control cardiac arrhythmia Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Serious nonhealing would , ulcer , bone fracture Abdominal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within past 28 day Significant traumatic injury within past 28 day Acute bacterial fungal infection require IV antibiotic time study registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy within past 14 day AIDS base upon current CDC definition ( HIV test require ) No condition would impair ability swallow pill ( e.g. , GI tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) No disease would obscure toxicity dangerously alter drug metabolism Not dialysis No history chronic hepatitis B C NOTE : **Required patient receive prior bevacizumab develop know clinically significant nephrotic syndrome treatment whose baseline value return normal . PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered toxic effect prior therapy Prior interstitial brachytherapy , Gliadel wafer , stereotactic radiosurgery allow provide confirmation progressive disease PET scan , thallium scan , MRI spectroscopy , perfusion MRI , surgical documentation No 3 prior treatment regimen ( phase I* ) No 2 prior treatment regimen recurrent glioblastoma/gliosarcoma ( phase II* ) More 28 day since prior major surgical procedure open biopsy ( exception craniotomy ) At least 28 day since prior investigational agent cytotoxic agent ( 42 day nitrosoureas , 21 day procarbazine , 14 day vincristine ) At least 14 day since prior noncytotoxic agent ( e.g. , bevacizumab , interferon , tamoxifen , thalidomide , isotretinoin , tyrosine kinase inhibitor ) No concurrent highlyactive antiretroviral therapy No concurrent herbal product unknown constitution No concurrent major surgical procedure NOTE : *Phase I close phase II open 3/6/12 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>